Our operational model is to establish for every project dedicated teams and accounting fitting the needs of our donators. 

Academic research and start-ups constantly discover new treatment options for patients, but often lack the time, resources, ability, or know-how to bring them to the clinical trial stage. On the other hand, pharmaceutical industry and investors prefer investing in drugs with established preclinical and early clinical safety and their interest in innovative therapeutics is, as a rule, proportional to commercial prospects rather than patient needs.